newsletter3

banner-about

Press Room

New Data in New England Journal of Medicine on Chronic Kidney Disease

Denmark, November 10, 2015.

A study in the New England Journal of Medicine published on November 5 shows that suPAR reliably can predict the development of Chronic Kidney Disease up to five years before symptoms of this disease emerge - a disease that affects an estimated 600 million people.

Currently, physicians rely on two markers to monitor existing kidney disease, but they are not sensitive enough to predict a persons risk of developing the disease or to catch it in its early stages.

The New England Journal of Medicine study found that a high suPAR level was an excellent predictor of future kidney disease.
"We can now stratify people according to their risk of developing kidney disease using suPAR levels" said Dr. Salim Hayek, first author of the study.

The study is even a significant breakthrough in preventive medicine. Also diabetes patients, of which about one-third develop Diabetic Kidney Disease, can now be helped.
"This will help risk-stratify patients with diabetes on their risk of future kidney disease" explains Jochen Reiser, senior author of the NEJM study.

Results are based upon research using the suPARnostic® products from ViroGates.

Jakob Knudsen, CEO of ViroGates comments: " We are pleased that our products can help to identify patients in risk of developing chronic kidney disease earlier than what has been possible to date, and we look forward to help the medical community use these results in clinical practice".

More information here:

Read the entire press release here

The New England Journal of Medicine article and abstract
http://www.nejm.org/doi/full/10.1056/NEJMoa1506362

An editorial explaining and commenting on the data
http://www.nejm.org/doi/full/10.1056/NEJMe1512997?rss=searchAndBrowse

ScienceDaily comment on the data set
http://www.sciencedaily.com/releases/2015/11/151105151925.htm

Meet us at EuSEM 2015 in Torino and ACC 2015 in Vienna

Denmark, October 8, 2015.

Come and meet us at the following Emergency Medicine Conferences - and hear about the Quantitative suPARnostic® Quick Triage product!

EuSEM 2015

October 11-13: EuSEM 2015 in Torino, Italy - The largest meeting of Emergency Medicine in Europe.

Emergency Medicine is drawing more and more attention as the number of patients in Emergency Departments is growing rapidly each year.

The suPARnostic® Quick Triage test is a Point of Care Test Device and a triaging aid for patient risk prognosis for clinicians in Emergency Medicine.

Meet us at the ViroGates booth no. 24 in the exhibition area, where we will be giving product presentations of the Quantitative suPARnostic® Quick Triage test during the breaks.

Jakob Knudsen, CEO and Jesper Eugen-Olsen, CSO, will be present together with our distributor B.S.N.

There will also be a poster by PhD Student Line Jee Rasmussen, Hvidovre Hospital with the title;

“Low values of the inflammatory biomarker suPAR is a good predictor of low risk of readmission and mortality in the acute care setting”.

Please find more information on the congress here: EuSEM Congress 2015

 ACC2015 2

October 17-18: ACC 2015 in Vienna, Austria - Acute Cardiovascular Care.

ACC is the largest meeting in Europe with focus on Acute Cardiovascular diseases, and the topic "Innovating to Improve Acute Cardiovascular Care" this year.

The suPARnostic® Quick Triage test is a triaging aid for patient risk prognosis in Acute Care - also in the cardiovascular area.

The lateral flow test will determine the level of suPAR in only 20 minutes, giving the clinician a better tool to determine the severity of the patients prognosis.

Meet us at the ViroGates booth no. B3 in the exhibition area, where we will be giving product presentations of the Quantitative suPARnostic® Quick Triage test during the breaks.

Jakob Knudsen, CEO and Jesper Eugen-Olsen, CSO, will be present.

Please find more information about the congress here: ACC2015

For more information about the Quantitative suPARnostic® Quick Triage test look here 

suPAR Poster wins prize at ESC2015

Denmark, September 3, 2015.

MD Gethin Hodges from Glostrup Hospital, Denmark, was elected for a moderated poster presentation at the ESC Congress 2015, European Society of Cardiology in London, with his poster titled;

"suPAR is Associated with Cardiovascular Events and Mortality in Patients with Asymptomatic Aortic Stenosis".

His poster on suPAR and CVD was awarded with the prize "Best Moderated Poster" in his session!

Also read the abstract on the newly published article by Gethin Hodges in CJC, Canadian Journal of Cardiology, with the title; "suPAR: A New Biomarker for Cardiovascular Disease?"

 

DSKB Nyt - suPAR is a new Prognostic Biomarker in Clinical Routine

Denmark, September 1, 2015.

In the latest issue of DSKB Nyt no. 2/2015, Dansk Selskab for Klinisk Biokemi, is an article on suPAR - a new prognostic biomarker in clinical routine at Copenhagen University Hospital, Hvidovre, Denmark.

suPAR has since november 2013 been measured on all patients upon admission to the Emergency Department at Hvidovre Hospital using the suPARnostic® AUTO Flex Elisa assay, automated on the BEP2000 platform and analysed once every day. Preliminary results show, that suPAR is strongly correlated with mortality (30- and 90-days), and that suPAR kan help identify the patients at risk who should receive increased clinical attention.

In order for clinicians at the Emergency Department to be able to use the suPAR results even better in the clinical assessment of the patient, they need to receive the suPAR results faster, together with other test results taken.

Hvidovre Hospitals Clinical Biochemical Department is therefore working on developing a new suPAR immunoturbidimetry assay on the COBAS 6000, to bring down the analysis time.

More information in the article (in Danish) here;
"Indførelse af suPAR som ny prognostisk biomarkør i klinisk rutine"

suPAR and CVD Poster Presentation at ESC 2015 in London

Denmark, August 10, 2015.

Come and hear the poster presentation about suPAR and CVD by MD Gethin Hodges (Glostrup Hospital, Denmark) at the ESC2015 Conference (European Society of Cardiology) in London, August 29 - September 2.

The title is; "suPAR is associated with cardiovascular events and mortality in patients with asymptomatic aortic stenosis"

The moderated poster presentation will take place on August 31 at 16.12 in the poster area, session number 335.

Also read the abstract on the newly published article by Gethin Hodges in CJC, Canadian Journal of Cardiology, with the title; "suPAR: A New Biomarker for Cardiovascular Disease?"

Please find the abstract in PubMed here;  suPAR: A New Biomarker for Cardiovascular Disease?

Archive

Contact us

virogates logo2
Blokken 45

3460 Birkerød
Denmark

Phone +45 21 13 13 36
Skype: virogates
CVR No.: 25734033
E-mail: info@virogates.com

 in-2  tw-2